The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I):
wherein R
1
is optionally substituted C1-C8 alkyl and the like; R
2
is C1-C6 alkyl; R
3
is C1-C6 alkyl and the like; or R
2
and R
3
taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R
4
is hydrogen and the like; G is a group selected from the groups shown by the formula an the like:
wherein R
5
is hydrogen and the like; X
1
is a single bond and the like; X
2
is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R
6
)—, wherein R
6
is hydrogen and the like, and the like; X
3
is a single bond and the like;
a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.
There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity:
wherein R1, R2, R3, R4, and R5 in the formula (1) each has the same meaning as defined in the specification.